other benefits of tirzepatide in Sun City AZ: A Treatment for Weight Loss Tirzepatide Beyond Diabetes and Obesity:

Mild reactions may allow continuation under a doctor's supervision

Research shows that GLP-1 receptor agonists improve cholesterol profiles in people with obesity and metabolic syndrome, making them valuable tools for cardiovascular health

That single-molecule dual agonism makes it one of the most-studied research peptides in metabolic and incretin biology today

In people with obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg resulted in 20% reduction in major adverse cardiovascular events [(MACE), death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke] compared to placebo (SELECT trial) after a mean follow-up of 39.8 months this is the first trial demonstrating cardiovascular benefit for an obesity pharmacotherapy [110]

Rybelsus has the advantage of not needing refrigeration before dispensing, which is a minor convenience